Physician profile
Xian Li
NPI 1396092854
$2,715.16
in general payments reported to CMS, 2019-2025
13 companies · $308 in 2025
The $308 reported for 2025 was more than what 84% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $192 · 2020: $304 · 2021: $486 · 2022: $532 · 2023: $489 · 2024: $404 · 2025: $308.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,201.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,201.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,820.73 | 2019-2025 | Trulance, Xifaxan |
| Astrazeneca Pharmaceuticals LP | $357.70 | 2019-2025 | Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $181.63 | 2022-2023 | Jardiance |
| Abbvie INC. | $94.74 | 2025 | |
| Merck Sharp & Dohme LLC | $79.63 | 2020-2025 | Capvaxive, Gardasil, Gardasil 9 |
| Hikma Pharmaceuticals USA | $34.24 | 2019 | |
| La Jolla Pharmaceutical Company | $30.50 | 2025 | Xacduro |
| Agepha Pharma Fz LLC | $23.20 | 2025 | Lodoco |
| Janssen Pharmaceuticals, INC | $22.42 | 2024 | Xarelto |
| Chiesi USA, INC. | $20.36 | 2025 | Cleviprex |
| Genentech USA, INC. | $19.82 | 2019 | |
| Smith+Nephew, INC. | $16.31 | 2024 | Collagenase Santyl |
| Evoke Pharma, INC. | $13.88 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Xian Li listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.